Retatrutide

What Is Retatrutide?

Retatrutide — designated LY3437943 in clinical development and colloquially referred to as "RETA peptide" — is a synthetic acylated peptide developed by Eli Lilly and Company. It represents the most receptor-comprehensive incretin-based therapeutic currently in clinical development, functioning as a simultaneous agonist at three distinct G-protein coupled receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIP-R), and the glucagon receptor (GCGR).

This triple-agonist architecture distinguishes retatrutide from all currently approved incretin therapies. Semaglutide (marketed as Ozempic and Wegovy) targets GLP-1R exclusively. Tirzepatide (Mounjaro and Zepbound) adds GIP-R agonism to the GLP-1R target. Retatrutide's addition of glucagon receptor agonism introduces a third metabolic lever — one that is theorized to drive substantially greater energy expenditure and hepatic fat mobilization than dual agonism alone.

"Retatrutide produced a mean weight reduction of 24.2% at 48 weeks in participants with obesity — a magnitude of effect approaching that of bariatric surgery and substantially exceeding any previously approved pharmacological intervention."

— Jastreboff et al., New England Journal of Medicine, 2023

?

In Plain English — What Does This Actually Mean?

The short version: Retatrutide is the next generation of the same class of drugs as Ozempic and Mounjaro — but it pulls three levers instead of one or two. Ozempic tells your brain you're full. Mounjaro does that plus improves how your body handles blood sugar. Retatrutide does both of those things and tells your body to burn more calories at rest. That's why the weight loss numbers are bigger.

Why the Phase 2 results matter: In the clinical trial published in the New England Journal of Medicine — one of the most prestigious medical journals in the world — people taking the highest dose lost an average of 24% of their body weight in under a year. To put that in perspective, that's roughly what bariatric surgery achieves. No pill or injection had ever come close to that before. It's a genuinely significant result.

Where it stands right now: Retatrutide is not approved yet — it's in Phase 3 trials, which is the final stage before FDA review. Eli Lilly (the same company that makes Mounjaro) is running those trials now. Research-grade retatrutide is available from Purgo Labs for laboratory investigation only — it is not for human use outside of clinical trial settings.

Bottom line: If semaglutide was the iPhone 12 and tirzepatide was the iPhone 14, retatrutide is the iPhone 16. Same concept, meaningfully more powerful.

Triple Receptor Mechanism of Action

Understanding retatrutide's mechanism requires appreciating how each of its three receptor targets contributes to the overall metabolic effect. The three pathways are synergistic rather than merely additive.

GLP-1R Agonism

• Stimulates glucose-dependent insulin secretion from pancreatic β-cells

• Suppresses glucagon release from α-cells, reducing hepatic glucose output

• Slows gastric emptying, prolonging satiety after meals

• Acts on hypothalamic arcuate nucleus to suppress appetite via POMC/AgRP signaling

• Reduces food reward signaling in mesolimbic dopamine pathways

GIP-R Agonism

• Enhances glucose-dependent insulin secretion (synergistic with GLP-1R)

• May improve adipose tissue insulin sensitivity and lipid storage dynamics

• Attenuates GLP-1R-mediated nausea — potentially improving tolerability at higher doses

• Promotes bone formation and may have direct central appetite-suppressing effects

• Modulates energy balance in adipose tissue via sympathetic nervous system

GCGR Agonism

• Increases hepatic glucose output (counterbalanced by GLP-1R insulin stimulation)

• Markedly increases energy expenditure via thermogenic mechanisms

• Promotes hepatic lipolysis and reduces liver fat content (NAFLD/NASH relevance)

• Increases fatty acid oxidation in skeletal muscle and liver

• Contributes to the enhanced weight loss beyond dual agonism